These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12384366)

  • 1. Resistance to beta-lactamase inhibitor protein does not parallel resistance to clavulanic acid in TEM beta-lactamase mutants.
    Schroeder WA; Locke TR; Jensen SE
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3568-73. PubMed ID: 12384366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.
    Vakulenko S; Golemi D
    Antimicrob Agents Chemother; 2002 Mar; 46(3):646-53. PubMed ID: 11850243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
    Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R
    FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.
    Vakulenko SB; Geryk B; Kotra LP; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1542-8. PubMed ID: 9660980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
    Thomson JM; Distler AM; Bonomo RA
    Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime.
    Imtiaz U; Manavathu EK; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 1994 May; 38(5):1134-9. PubMed ID: 8067751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TEM-121, a novel complex mutant of TEM-type beta-lactamase from Enterobacter aerogenes.
    Poirel L; Mammeri H; Nordmann P
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4528-31. PubMed ID: 15561821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
    Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
    Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
    Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
    J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular epidemiology of the plasmid-encoded TEM-1 beta-lactamase in Scotland.
    Thomson CJ; Amyes SG
    Epidemiol Infect; 1993 Feb; 110(1):117-25. PubMed ID: 8432315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine mapping of the sequence requirements for binding of beta-lactamase inhibitory protein (BLIP) to TEM-1 beta-lactamase using a genetic screen for BLIP function.
    Yuan J; Huang W; Chow DC; Palzkill T
    J Mol Biol; 2009 Jun; 389(2):401-12. PubMed ID: 19389404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.
    Stapleton PD; Shannon KP; French GL
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1881-7. PubMed ID: 10428907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TEM-184, a Novel TEM-Derived Extended-Spectrum β-Lactamase with Enhanced Activity against Aztreonam.
    Piccirilli A; Perilli M; Amicosante G; Conte V; Tascini C; Rossolini GM; Giani T
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of aspartate 49 and phenylalanine 142 residues of a tight binding inhibitory protein of beta-lactamases.
    Petrosino J; Rudgers G; Gilbert H; Palzkill T
    J Biol Chem; 1999 Jan; 274(4):2394-400. PubMed ID: 9891008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo selection of a complex mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during ceftazidime therapy.
    Jacquier H; Marcadé G; Raffoux E; Dombret H; Woerther PL; Donay JL; Arlet G; Cambau E
    J Antimicrob Chemother; 2013 Dec; 68(12):2792-6. PubMed ID: 23861309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
    Franceschini N; Perilli M; Segatore B; Setacci D; Amicosante G; Mazzariol A; Cornaglia G
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1459-62. PubMed ID: 9624494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detrimental effect of the combination of R164S with G238S in TEM-1 beta-lactamase on the extended-spectrum activity conferred by each single mutation.
    Giakkoupi P; Tzelepi E; Tassios PT; Legakis NJ; Tzouvelekis LS
    J Antimicrob Chemother; 2000 Jan; 45(1):101-4. PubMed ID: 10629019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-function studies of arginine at position 276 in CTX-M beta-lactamases.
    Pérez-Llarena FJ; Cartelle M; Mallo S; Beceiro A; Pérez A; Villanueva R; Romero A; Bonnet R; Bou G
    J Antimicrob Chemother; 2008 Apr; 61(4):792-7. PubMed ID: 18281307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.